The present invention provides novel PSMA targeting urea-based ligands that binds to prostate-specific membrane antigen (PSMA) which is expressed 8-to-12-fold higher in prostate cancer cells when compared to healthy tissue. The PSMA targeting urea-based ligands comprises a chelating agent that may comprise a metal and a halogen radioisotope of fluorine, iodine, bromine or astatine. The invention further relates to a method for providing the PSMA targeting urea-based ligands of the invention, to precursors of the PSMA targeting urea-based ligands and to the PSMA targeting urea-based ligands use in radiotherapy, imaging and theranostic.

The invention comprises novel methods and compositions for detecting whether a patient will be responsive to ALK inhibitors and methods of treating the patient.

A visualizable radioactive carbon microsphere (CMS) suspension, a preparation method, and a use thereof are provided. Every 1 mL of the visualizable radioactive CMS suspension includes: CMS: 10 mg to 500 mg; a therapeutic radionuclide with an activity of 5 mCi to 500 mCi; an imaging radionuclide with an activity of 0.1 mCi to 100 mCi; a small organic molecule: 0 mg to 100 mg; and a first solution: 0.1 mL to 1.0 mL. The preparation method mainly includes a process of allowing the CMS to adsorb the small organic molecule, the therapeutic radionuclide, and the imaging zirconium [.sup.89Zr]. The visualizable radioactive CMS suspension can realize both local radiotherapy and real-time imaging of a solid tumor lesion, and thus achieves the visualized treatment of a tumor, which provides a new radioactive CMS product that integrates diagnosis and treatment.

The present invention relates to a ligand-SIF A-chelator conjugate, comprising, within in a single molecule three separate moieties: (a) one or more ligands which are capable of binding to a disease-relevant target molecule, (b) a silicon-fluoride acceptor (SIFA) moiety which comprises a covalent bond between a silicon atom and a fluorine atom, and (c) one or more chelating groups, optionally containing a chelated nonradioactive or radioactive cation.

A method of treating infection and/or inflammation in a subject includes steps of providing a polyester biomaterial comprising diol monomers and at least first carboxylate monomers, wherein the first carboxylate monomers are itaconate; and administering the polyester biomaterial to the subject. The polyester biomaterial can be in the form of a biomimetic, and characterized by hydrolytic degradability. The polyester biomaterial may further include second carboxylate monomers. The biomaterial can be poly(itaconate-co-citrate-co-octanediol).

The present disclosure provides compositions for in vivo imaging of hydrogen peroxide; and methods for detecting hydrogen peroxide in vivo. The compositions and methods find use in various diagnostic applications, which are also provided.

The present invention relates generally to the field of nutrition, health and wellness. In particular the present invention relates to probiotics and ways to increase their effectiveness. One embodiment of the present invention relates to a combination of probiotics with SIgA and possible uses of this combination. For example a use of a composition comprising SIgA and at least one probiotic for the preparation of a product to treat or prevent inflammation is disclosed.

A method of preparing a .sup.64Cu-BaBaSar-RGD.sub.2 solution is provided. The method includes lyophilizing a solution of BaBaSar-RGD.sub.2 and adding a .sup.64Cu solution to the lyophilized BaBaSar-RGD.sub.2.

Disclosed are chelates resulting from the complexation of bifunctional do2pa derivatives ligands of formula (I), wherein the substituents R.sup.1, R.sup.1′, R.sup.2, R.sup.2′, R.sup.3, R.sup.3′, L.sup.1, L.sup.1′, L.sup.2 and L.sup.2′ are defined as in the claims, with metallic cations, especially Pb(II) and Bi(III). Also disclosed are bifunctional do2pa derivatives ligands of formula (I), as well as the use of chelates in nuclear medicine and the use of ligands in cations detection or epuration of effluents.

##STR00001##

The present disclosure relates to devices, systems, and methods for screening compounds and materials for otoxicity and otoprotective activity. In particular, the present invention relates to a model organism (e.g., Danio rerio) and system for measuring behavior associated with hair cell loss.